Skip Navigation

Neuro-Oncology 2004 6(2):96-103; doi:10.1215/S1152851703000231
© 2004 by Society
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Brat, D. J.
Right arrow Articles by Curran, W. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Brat, D. J.
Right arrow Articles by Curran, W. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 by the Society forNeuro-Oncology

Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-gradeastrocytomas using fluorescence in situ hybridization on tissue microarraysfrom Radiation Therapy Oncology Group trials

Daniel J. Brat2, Wendy F. Seiferheld, Arie Perry, Elizabeth H. Hammond, Kevin J. Murray, Alan R. Schulsinger, Minesh P. Mehta and Walter J. Curran

Radiation Therapy Oncology Group (RTOG) TranslationalResearch Program, Philadelphia, PA: Departments of Pathology and LaboratoryMedicine, Emory University School of Medicine, Atlanta, GA 30322(D.J.B.); RTOG Statistical Division, Philadelphia, PA19107 (W.F.S.); Division of Neuropathology, WashingtonUniversity School of Medicine, St. Louis, MO 63110 (A.P.); Department of Pathology, LDS Hospital, Salt Lake City, UT84143 (E.H.H.); Department of Radiation Oncology,Medical College of Wisconsin, Milwaukee, WI 53226 (K.J.M.); Department of Radiation Oncology, SUNY Health SciencesCenter, Brooklyn, NY 11203 (A.R.S.); Department ofHuman Oncology, University of Wisconsin Medical School, Madison, WI 53792(M.P.M.); Department of Radiation Oncology, JeffersonMedical College, Philadelphia, PA 19107 (W.J.C.); USA

2 Address correspondence to Daniel J. Brat, Department of Pathology andLaboratory Medicine, Emory University Hospital H-176, 1364 Clifton Road NE,Atlanta, GA 30322(dbrat{at}emory.edu).


  Abstract

Survival periods vary considerably for patients with high-gradeastrocytomas, and reliable prognostic markers are not currently available. Wetherefore investigated whether genetic losses from chromosomes 1p, 19q, 9p, or10q were associated with survival in 89 high-grade astrocytomas using tissuemicroarrays (TMAs) derived from Radiation Therapy Oncology Group clinicaltrials. Cases included 15 anaplastic astrocytomas (AAs) and 74 glioblastomas(GBMs) selected on the basis of survival times significantly shorter or longerthan the expected median. Genetic analysis was performed by TMA-fluorescencein situ hybridization (FISH) on array sections using 8 DNA probes, includingthose directed at 1p32, 19q13.4, 9p21 (p16/CDKN2A), and 10q(PTEN and DMBT1). Genetic status for each locus wascorrelated with patient survival group, and data were analyzed by usingFisher's exact test of association (adjusted P = 0.025). Losses ofchromosome 1p, either alone or in combination with 19q, were encountered inonly 2 cases, both AAs. This contrasts with oligodendrogliomas, in whichcombined 1p and 19q losses are frequent and predictive of prolonged survival.Solitary 19q loss was noted in 3/15 AAs and in 7/70 GBMs and was more frequentin the long-term survival group (P = 0.041, AA and GBM combined).Chromosome 9p loss was seen in 5/8 AAs and 39/57 GBMs, whereas chromosome 10qloss was detected in 4/15 AAs and 48/68 GBMs. The 9p and 10q deletions wereslightly more frequent in short-term survivors, though none of the comparisonsachieved statistical significance. Long-term and short-term survival groups ofhigh-grade astrocytomas appear to have dissimilar frequencies of 19q, 9p, and10q deletions. TMA-FISH is a rapid and efficient way of evaluating geneticalterations in such tumors.

Received May 21, 2003; Accepted September 24, 2003


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
Y. Hitoshi, B. T. Harris, H. Liu, B. Popko, and M. A. Israel
Spinal Glioma: Platelet-Derived Growth Factor B-Mediated Oncogenesis in the Spinal Cord
Cancer Res., October 15, 2008; 68(20): 8507 - 8515.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
D. Krex, B. Klink, C. Hartmann, A. von Deimling, T. Pietsch, M. Simon, M. Sabel, J. P. Steinbach, O. Heese, G. Reifenberger, et al.
Long-term survival with glioblastoma multiforme
Brain, October 1, 2007; 130(10): 2596 - 2606.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. R. Miller, C. P. Dunham, B. W. Scheithauer, and A. Perry
Significance of Necrosis in Grading of Oligodendroglial Neoplasms: A Clinicopathologic and Genetic Study of Newly Diagnosed High-Grade Gliomas
J. Clin. Oncol., December 1, 2006; 24(34): 5419 - 5426.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Liu, P. J. Park, W. Lai, E. Maher, A. Chakravarti, L. Durso, X. Jiang, Y. Yu, A. Brosius, M. Thomas, et al.
A Genome-Wide Screen Reveals Functional Gene Clusters in the Cancer Genome and Identifies EphA2 as a Mitogen in Glioblastoma
Cancer Res., November 15, 2006; 66(22): 10815 - 10823.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. N. Sarkaria, B. L. Carlson, M. A. Schroeder, P. Grogan, P. D. Brown, C. Giannini, K. V. Ballman, G. J. Kitange, A. Guha, A. Pandita, et al.
Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.
Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2264 - 2271.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.